353 related articles for article (PubMed ID: 21879846)
1. Nitroimidazoles for the treatment of TB: past, present and future.
Mukherjee T; Boshoff H
Future Med Chem; 2011 Sep; 3(11):1427-54. PubMed ID: 21879846
[TBL] [Abstract][Full Text] [Related]
2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
4. PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
Dawson R; Diacon A
Expert Opin Investig Drugs; 2013 Jul; 22(7):927-32. PubMed ID: 23687915
[TBL] [Abstract][Full Text] [Related]
5. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Lienhardt C; Vernon A; Raviglione MC
Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
[TBL] [Abstract][Full Text] [Related]
6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
[TBL] [Abstract][Full Text] [Related]
9. New anti-tuberculosis drugs with novel mechanisms of action.
Rivers EC; Mancera RL
Curr Med Chem; 2008; 15(19):1956-67. PubMed ID: 18691051
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
[TBL] [Abstract][Full Text] [Related]
11. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
12. Molecular Players in Tuberculosis Drug Development: Another Break in the Cell Wall.
Squeglia F; Romano M; Ruggiero A; Berisio R
Curr Med Chem; 2017 Nov; 24(36):3954-3969. PubMed ID: 28183257
[TBL] [Abstract][Full Text] [Related]
13. The TB Alliance: overcoming challenges to chart the future course of TB drug development.
Ginsberg A
Future Med Chem; 2011 Aug; 3(10):1247-52. PubMed ID: 21859299
[TBL] [Abstract][Full Text] [Related]
14. Current development and future prospects in chemotherapy of tuberculosis.
Nuermberger EL; Spigelman MK; Yew WW
Respirology; 2010 Jul; 15(5):764-78. PubMed ID: 20546189
[TBL] [Abstract][Full Text] [Related]
15. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
17. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
[TBL] [Abstract][Full Text] [Related]
18. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
[TBL] [Abstract][Full Text] [Related]
19. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
20. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
